GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Psyence Biomedical Ltd (NAS:PBM) » Definitions » ROE %

Psyence Biomedical (Psyence Biomedical) ROE % : -418.80% (As of Mar. 2023)


View and export this data going back to 2024. Start your Free Trial

What is Psyence Biomedical ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Psyence Biomedical's annualized net income for the quarter that ended in Mar. 2023 was $-3.10 Mil. Psyence Biomedical's average Total Stockholders Equity over the quarter that ended in Mar. 2023 was $0.74 Mil. Therefore, Psyence Biomedical's annualized ROE % for the quarter that ended in Mar. 2023 was -418.80%.

The historical rank and industry rank for Psyence Biomedical's ROE % or its related term are showing as below:

PBM' s ROE % Range Over the Past 10 Years
Min: -418.8   Med: -237.61   Max: -56.42
Current: -418.8

During the past 3 years, Psyence Biomedical's highest ROE % was -56.42%. The lowest was -418.80%. And the median was -237.61%.

PBM's ROE % is ranked worse than
94.71% of 1362 companies
in the Biotechnology industry
Industry Median: -44.1 vs PBM: -418.80

Psyence Biomedical ROE % Historical Data

The historical data trend for Psyence Biomedical's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psyence Biomedical ROE % Chart

Psyence Biomedical Annual Data
Trend Mar21 Mar22 Mar23
ROE %
- -56.42 -418.80

Psyence Biomedical Semi-Annual Data
Mar21 Mar22 Mar23
ROE % - -56.42 -418.80

Competitive Comparison of Psyence Biomedical's ROE %

For the Biotechnology subindustry, Psyence Biomedical's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Psyence Biomedical's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Psyence Biomedical's ROE % distribution charts can be found below:

* The bar in red indicates where Psyence Biomedical's ROE % falls into.



Psyence Biomedical ROE % Calculation

Psyence Biomedical's annualized ROE % for the fiscal year that ended in Mar. 2023 is calculated as

ROE %=Net Income (A: Mar. 2023 )/( (Total Stockholders Equity (A: Mar. 2022 )+Total Stockholders Equity (A: Mar. 2023 ))/ count )
=-3.097/( (1.677+-0.198)/ 2 )
=-3.097/0.7395
=-418.80 %

Psyence Biomedical's annualized ROE % for the quarter that ended in Mar. 2023 is calculated as

ROE %=Net Income (Q: Mar. 2023 )/( (Total Stockholders Equity (Q: Mar. 2022 )+Total Stockholders Equity (Q: Mar. 2023 ))/ count )
=-3.097/( (1.677+-0.198)/ 2 )
=-3.097/0.7395
=-418.80 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is one times the annual (Mar. 2023) net income data. ROE % is displayed in the 30-year financial page.


Psyence Biomedical  (NAS:PBM) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2023 )
=Net Income/Total Stockholders Equity
=-3.097/0.7395
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-3.097 / 0)*(0 / 1.6895)*(1.6895 / 0.7395)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*2.2847
=ROA %*Equity Multiplier
=N/A %*2.2847
=-418.80 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2023 )
=Net Income/Total Stockholders Equity
=-3.097/0.7395
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-3.097 / -3.097) * (-3.097 / -3.125) * (-3.125 / 0) * (0 / 1.6895) * (1.6895 / 0.7395)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.991 * N/A % * 0 * 2.2847
=-418.80 %

Note: The net income data used here is one times the annual (Mar. 2023) net income data. The Revenue data used here is one times the annual (Mar. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Psyence Biomedical ROE % Related Terms

Thank you for viewing the detailed overview of Psyence Biomedical's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Psyence Biomedical (Psyence Biomedical) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
121 Richmond Street West, Penthouse Suite 1300, Toronto, ON, CAN, M5H 2K1
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed ISO22000 facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Psyence Biomedical (Psyence Biomedical) Headlines